Share This Page
Suppliers and packagers for generic pharmaceutical drug: olodaterol hydrochloride; tiotropium bromide
✉ Email this page to a colleague
olodaterol hydrochloride; tiotropium bromide
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | STIOLTO RESPIMAT | olodaterol hydrochloride; tiotropium bromide | SPRAY, METERED;INHALATION | 206756 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0155-28 | 1 CARTRIDGE in 1 CARTON (0597-0155-28) / 28 SPRAY, METERED in 1 CARTRIDGE | 2015-05-21 |
| Boehringer Ingelheim | STIOLTO RESPIMAT | olodaterol hydrochloride; tiotropium bromide | SPRAY, METERED;INHALATION | 206756 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0155-61 | 1 CARTRIDGE in 1 CARTON (0597-0155-61) / 60 SPRAY, METERED in 1 CARTRIDGE | 2015-05-21 |
| Boehringer Ingelheim | STIOLTO RESPIMAT | olodaterol hydrochloride; tiotropium bromide | SPRAY, METERED;INHALATION | 206756 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0155-70 | 1 CARTRIDGE in 1 CARTON (0597-0155-70) / 10 SPRAY, METERED in 1 CARTRIDGE | 2015-05-21 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Global Suppliers of Olodaterol Hydrochloride and Tiotropium Bromide
This report identifies key global suppliers of Olodaterol Hydrochloride and Tiotropium Bromide, active pharmaceutical ingredients (APIs) used in the treatment of chronic obstructive pulmonary disease (COPD). The analysis focuses on manufacturers with demonstrated production capacity and regulatory filings, crucial for R&D and investment decisions in the respiratory drug market.
Key Suppliers of Olodaterol Hydrochloride
Olodaterol Hydrochloride is a long-acting beta2-adrenergic agonist (LABA) used in combination therapies for COPD. The supply chain for this API is concentrated among a few specialized manufacturers.
Major Manufacturers
Boehringer Ingelheim is the originator and primary manufacturer of Olodaterol Hydrochloride. As the innovator, they hold the primary patents and control the initial supply. Their production is integrated into their own final drug product formulations.
Beyond the originator, contract manufacturing organizations (CMOs) and specialized API producers have emerged to support the broader market. These suppliers are critical for generic development and ensuring market competition.
| Supplier Name | Location | Primary Role | Regulatory Approvals (Examples) | Notes |
|---|---|---|---|---|
| Boehringer Ingelheim | Germany | Originator, Integrated Manufacturing | FDA, EMA | Primary source; also produces finished dosage forms. |
| WuXi AppTec | China | Contract Development and Manufacturing (CDMO) | FDA, EMA | Offers custom synthesis and large-scale API manufacturing. |
| Lonza Group AG | Switzerland | CDMO | FDA, EMA | Provides custom API manufacturing services, including complex synthesis. |
| Cipla Limited | India | API Manufacturer, Generic Producer | FDA, EMA | Involved in both API production and development of generic formulations. |
| Dr. Reddy's Laboratories | India | API Manufacturer, Generic Producer | FDA, EMA | Significant presence in API manufacturing for global markets. |
Production Capacity and Trends
The production of Olodaterol Hydrochloride requires sophisticated synthetic chemistry capabilities. Manufacturers are assessed based on their adherence to Good Manufacturing Practices (GMP) and their ability to scale production to meet global demand. Capacity is generally considered sufficient, with a focus on quality control and regulatory compliance.
Regulatory Landscape
API suppliers for Olodaterol Hydrochloride must comply with stringent regulatory requirements from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Successful Drug Master File (DMF) submissions are essential for market access.
Key Suppliers of Tiotropium Bromide
Tiotropium Bromide is a long-acting muscarinic antagonist (LAMA) also used in COPD treatment, often in combination with LABAs. The supplier landscape for Tiotropium Bromide is more diverse, reflecting its longer history as a therapeutic agent and broader generic market penetration.
Major Manufacturers
Several established API manufacturers and specialized chemical companies produce Tiotropium Bromide. The key criteria for selection include purity, consistency, and adherence to pharmacopoeial standards.
| Supplier Name | Location | Primary Role | Regulatory Approvals (Examples) | Notes |
|---|---|---|---|---|
| Boehringer Ingelheim | Germany | Originator, Integrated Manufacturing | FDA, EMA | Primary developer and manufacturer of the original product. |
| Teva Pharmaceutical Industries | Israel | API Manufacturer, Generic Producer | FDA, EMA | A major player in generic APIs, including respiratory compounds. |
| Mylan N.V. (now Viatris) | Netherlands | API Manufacturer, Generic Producer | FDA, EMA | Significant global supplier of APIs and finished generic drugs. |
| Sun Pharmaceutical Industries | India | API Manufacturer, Generic Producer | FDA, EMA | One of the largest generic pharmaceutical companies globally. |
| Divi's Laboratories | India | API Manufacturer | FDA, EMA | Known for custom synthesis and large-scale API production. |
| Jubilant Life Sciences | India | API Manufacturer | FDA, EMA | Offers a broad portfolio of APIs, including respiratory agents. |
Production Capacity and Trends
The production of Tiotropium Bromide involves multi-step organic synthesis. Manufacturers are evaluated based on their capacity to produce high-purity API in bulk quantities. Market trends indicate a steady demand, driven by the prevalence of COPD globally. Suppliers are investing in process optimization to reduce costs and improve yields.
Regulatory Landscape
Suppliers of Tiotropium Bromide API must obtain approvals and maintain compliance with global regulatory bodies. This includes successful DMF submissions, site inspections, and adherence to ICH guidelines.
Comparative Analysis of Suppliers
When evaluating suppliers for Olodaterol Hydrochloride and Tiotropium Bromide, several factors are paramount for pharmaceutical companies and investors:
- Regulatory Compliance: Demonstrated history of successful FDA and EMA inspections and filings is non-negotiable.
- Quality Control: Robust quality management systems, including stringent analytical testing and batch-to-batch consistency.
- Production Scale and Reliability: Ability to produce sufficient quantities to meet market demand without disruption.
- Cost-Effectiveness: Competitive pricing without compromising quality or compliance.
- Intellectual Property (IP) Landscape: Understanding of patent protection for both the API and its manufacturing processes.
Olodaterol Hydrochloride: Originator vs. Generic Suppliers
Boehringer Ingelheim holds a strong position due to its originator status and integrated supply chain. For generic manufacturers, sourcing from qualified CMOs like WuXi AppTec or Lonza is critical for development and commercialization. Indian manufacturers like Cipla and Dr. Reddy's are also key players, offering competitive pricing and established regulatory track records. The competitive landscape for Olodaterol Hydrochloride is expected to intensify as more generic versions enter the market.
Tiotropium Bromide: Mature Market Dynamics
The Tiotropium Bromide market is more mature, with numerous generic suppliers. Companies like Teva, Viatris (formerly Mylan), and Sun Pharma are established leaders. Divi's Laboratories and Jubilant Life Sciences represent strong API-focused manufacturers. Competition is primarily driven by cost, quality, and supply chain reliability. Differentiation can come from specialized manufacturing expertise or unique IP related to process improvements.
Supply Chain Risks and Mitigation
- Geopolitical Instability: Concentration of manufacturing in specific regions (e.g., India, China) poses risks. Diversification of supply sources is a key mitigation strategy.
- Regulatory Changes: Evolving regulatory standards can impact compliance costs and timelines. Continuous monitoring of regulatory updates is essential.
- Raw Material Sourcing: Dependence on specific upstream suppliers for key starting materials can create vulnerabilities. Establishing multiple sourcing channels for critical raw materials reduces risk.
- Intellectual Property Disputes: Patent challenges and litigation can disrupt supply. Thorough IP due diligence is crucial.
Future Market Outlook
The market for both Olodaterol Hydrochloride and Tiotropium Bromide is expected to remain robust, driven by the global aging population and the persistent prevalence of COPD. Innovation in combination therapies and the development of new delivery devices will continue to influence demand. For API suppliers, maintaining high quality, ensuring regulatory adherence, and managing costs will be critical for sustained success.
Key Takeaways
- Boehringer Ingelheim is the primary originator and integrated manufacturer for both Olodaterol Hydrochloride and Tiotropium Bromide.
- The Olodaterol Hydrochloride API market is transitioning towards broader generic availability, with key CDMOs and Indian API manufacturers playing significant roles.
- The Tiotropium Bromide API market is mature, characterized by numerous global generic suppliers, with competition focused on cost, quality, and reliability.
- Regulatory compliance (FDA, EMA) and robust quality management systems are essential for all API suppliers.
- Supply chain diversification and proactive management of raw material sourcing are crucial for mitigating geopolitical and market risks.
Frequently Asked Questions
- What are the primary regulatory hurdles for new Olodaterol Hydrochloride API suppliers? New suppliers must establish robust quality management systems, demonstrate Good Manufacturing Practice (GMP) compliance through successful FDA and EMA inspections, and file comprehensive Drug Master Files (DMFs) detailing manufacturing processes, impurity profiles, and stability data.
- How does the patent landscape impact Tiotropium Bromide API sourcing? While the primary patents for Tiotropium Bromide itself have expired in many regions, process patents and patents on specific polymorphic forms or impurities can still influence sourcing decisions and the ability of certain manufacturers to produce the API cost-effectively and without infringement.
- Which regions are most dominant in the manufacturing of these APIs? India and China are dominant regions for API manufacturing due to competitive cost structures and established chemical synthesis capabilities. Europe, particularly Germany and Switzerland, remains significant for originator companies and specialized CDMOs.
- What are the typical lead times for API production for these compounds? Lead times can vary significantly based on supplier capacity, existing inventory, and the complexity of the current manufacturing schedule. For custom synthesis or large-volume orders, lead times can range from 3 to 9 months from order placement to delivery, following successful batch production and quality release.
- Are there any emerging technologies impacting the production of these APIs? Emerging technologies such as continuous manufacturing and flow chemistry are being explored to improve efficiency, reduce waste, and enhance the control of synthesis for complex molecules like Olodaterol Hydrochloride and Tiotropium Bromide. These technologies can potentially lead to more consistent product quality and reduced manufacturing costs.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/drug-master-file-dmf [2] European Medicines Agency. (n.d.). Active substances. Retrieved from https://www.ema.europa.eu/en/human-regulatory/manufacturing-quality/active-substances [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/page/ich-guidelines
More… ↓
